Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 4.6% during mid-day trading on Monday . The company traded as high as $4.00 and last traded at $3.83, with a volume of 115,199 shares trading hands. The stock had previously closed at $3.66.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating and issued a $12.00 target price on shares of Auris Medical Holding AG in a research note on Wednesday, June 15th. Finally, Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th.

The firm’s market capitalization is $129.60 million. The stock’s 50 day moving average price is $3.84 and its 200-day moving average price is $4.10.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.04. During the same quarter last year, the business posted ($0.28) EPS. On average, equities analysts predict that Auris Medical Holding AG will post ($1.01) EPS for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.